Business Context and Reporting Period
This Form 8-K Current Report was filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on July 16, 2018. The report details significant changes to the company's executive leadership, specifically the appointment of a new Chief Financial Officer and the departure of the incumbent.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: $250,000 per year.
- Discretionary Bonus: Up to 30% of base salary.
- Equity Grant: Option to purchase 150,000 shares of common stock.
- Option Exercise Price: $2.98 per share (based on July 16, 2018 closing price).
- Severance: Up to one year of base salary for termination without Cause or resignation for Good Reason; minimum of six months in the event of a Change of Control.
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Appointment: Robert Rankin was appointed Chief Financial Officer effective July 16, 2018.
- Departure: William R. Abbott ceased serving as Chief Financial Officer on July 16, 2018, with a final departure date of July 20, 2018.
Outlook, Risks, and Management Commentary
Management commentary is limited to the background of the new CFO, Robert Rankin, who brings over 20 years of experience, including previous CFO roles at Horsburgh & Scott and Process Fab, Inc. The filing notes that Mr. Rankin is an at-will employee. No specific financial guidance, market outlook, or new risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the exact vesting schedule for the 150,000 stock options granted to Robert Rankin (50,000 on first anniversary; 100,000 quarterly over two years).
- Confirm the definitions of "Cause," "Good Reason," and "Change of Control" in the attached Employment Agreement (Exhibit 10.1) to understand severance triggers.
- Review the press release (Exhibit 99.1) for any additional context regarding the leadership transition.
- Note that the filing date is July 16, 2018, and the report was signed on July 20, 2018.